The dark skin pigment melanin protects us from the sun’s damaging rays by absorbing light energy and converting it to heat. This could make it a very effective tool in tumor diagnosis and treatment, as demonstrated by a team from the Technical University of Munich (TUM) and Helmholtz Zentrum München. The scientists managed to create melanin-loaded cell membrane derived nanoparticles, which improved tumor imaging in an animal model while also slowing the growth of the tumor.
Nanoparticles are considered a promising weapon in the fight against tumors due to the fact that tumor tissue absorbs them more readily than healthy cells because their vascular system is more permeable. A good example is provided by outer membrane vesicles (OMVs), which are basically small bubbles surrounded by bacterial membrane.
These 20- to 200-nanometer particles are of interest because they are biocompatible, biodegradable and can be easily and inexpensively produced in bacteria, even in large volumes. Once loaded with medicinal active agents, they are easy to administer.
Nanoparticles carrying a black cargo
The huge potential of OMVs in tumor diagnosis and treatment has been demonstrated by Prof. Vasilis Ntziachristos, Professor of Biological Imaging at TUM, and his team. Their work builds on the characteristic properties of OMVs and melanin.
Dr. Vipul Gujrati, first author of the study, explains the principle: “Melanin absorbs light very readily – even in the infrared spectrum. We use precisely this light in our optoacoustic imaging technique for tumor diagnosis. It simultaneously converts this absorbed energy into heat, which is then emitted. Heat is also a way to combat tumors – other researchers are currently exploring this method in clinical trials.”
Optoacoustics, a method which has been significantly advanced by Ntziachristos, combines the benefits of optical imaging and ultrasound technology. Weak laser pulses gently heat the tissue, causing it to briefly expand very slightly. Ultrasound signals are produced when the tissue contracts again as it cools down. The measured signals vary depending on the tissue type. The scientists record them with special detectors and “translate” them into three-dimensional images. Sensor molecules or probes (such as OMVs) can improve the specificity and accuracy of the technique even further.
Heat build-up reduces tumor growth
The scientists initially had to overcome a problem specific to melanin: It is not very water-soluble and therefore difficult to administer. This is where the OMVs came into play. The researchers engineered bacteria in such a way that they produce melanin and store it in their membrane derived nanoparticles. They then tested the black nanoparticles in mice which had tumors in their lower back region. The particles were injected directly into the tumor, which was excited with infrared laser pulses as part of the optoacoustic procedure.
OMVs proved to be suitable sensor probes for this diagnosis technique because they delivered sharp, high-contrast images of the tumor. They are also well-suited to photothermal therapy approaches, where the tumor tissue is heated with stronger laser pulses in order to kill the cancer cells. The melanin in the nanoparticles caused the temperature of the tumor tissue to rise from 37 °C to up to 56 °C. Control tumors with no melanin only reached a maximum temperature of 39 °C. In the ten days following the treatment, the tumors grew at a significantly slower rate than those in the control group that had not received melanin OMVs. This heat effect was amplified by another positive effect of the particles: By causing a slight non-specific inflammation in the tumor tissue, the immune system was triggered to attack the tumor.
“Our melanin nanoparticles fit into the new medical field of theranostics – where therapy and diagnostics are combined. This makes them a highly interesting option for use in clinical practice,” says Ntziachristos. The scientists will now develop their OMVs further to bring them into clinical use in the future.
Prof. Vasilis Ntziachristos holds a chair at TUM. He is research group leader at the Central Institute for Translational Cancer Research at TUM (TranslaTUM) and Director of the Institute of Biological and Medical Imaging at Helmholtz Zentrum München.
Dr. Vipul Gujrati
Scientist at the Chair of Biological Imaging
Technical University of Munich
Tel.: +49 (0)89 3187 1244
Vipul Gujrati, Jaya Prakash, Jaber Malekzadeh-Najafabadi, Andre Stiel, Uwe Klemm, Gabriele Mettenleiter, Michaela Aichler, Axel Walch and Vasilis Ntziachristos: Bioengineered bacterial vesicles as biological nanoheaters for optoacoustic imaging, Nature Communications, March 7, 2019, DOI: 10.1038/s41467-019-09034-y
https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35324/ - This text on the web
https://www.cbi.ei.tum.de/en/labs/ - Research group headed by Vasilis Ntziachristos
http://www.professoren.tum.de/en/ntziachristos-vasilis/ - Profile of Vasilis Ntziachristos
Dr. Ulrich Marsch | Technische Universität München
UC San Diego cancer scientists identify new drug target for multiple tumor types
12.07.2019 | University of California - San Diego
Bacteria engineered as Trojan horse for cancer immunotherapy
04.07.2019 | Columbia University School of Engineering and Applied Science
For some phenomena in quantum many-body physics several competing theories exist. But which of them describes a quantum phenomenon best? A team of researchers from the Technical University of Munich (TUM) and Harvard University in the United States has now successfully deployed artificial neural networks for image analysis of quantum systems.
Is that a dog or a cat? Such a classification is a prime example of machine learning: artificial neural networks can be trained to analyze images by looking...
An international research group led by scientists from the University of Bayreuth has produced a previously unknown material: Rhenium nitride pernitride. Thanks to combining properties that were previously considered incompatible, it looks set to become highly attractive for technological applications. Indeed, it is a super-hard metallic conductor that can withstand extremely high pressures like a diamond. A process now developed in Bayreuth opens up the possibility of producing rhenium nitride pernitride and other technologically interesting materials in sufficiently large quantity for their properties characterisation. The new findings are presented in "Nature Communications".
The possibility of finding a compound that was metallically conductive, super-hard, and ultra-incompressible was long considered unlikely in science. It was...
An interdisciplinary research team at the Technical University of Munich (TUM) has built platinum nanoparticles for catalysis in fuel cells: The new size-optimized catalysts are twice as good as the best process commercially available today.
Fuel cells may well replace batteries as the power source for electric cars. They consume hydrogen, a gas which could be produced for example using surplus...
The fly agaric with its red hat is perhaps the most evocative of the diverse and variously colored mushroom species. Hitherto, the purpose of these colors was...
Physicists at the Max Planck Institute for Nuclear Physics in Heidelberg report the first result of the new Alphatrap experiment. They measured the bound-electron g-factor of highly charged (boron-like) argon ions with unprecedented precision of 9 digits. In comparison with a new highly accurate quantum electrodynamic calculation they found an excellent agreement on a level of 7 digits. This paves the way for sensitive tests of QED in strong fields like precision measurements of the fine structure constant α as well as the detection of possible signatures of new physics. [Physical Review Letters, 27 June 2019]
Quantum electrodynamics (QED) describes the interaction of charged particles with electromagnetic fields and is the most precisely tested physical theory. It...
24.06.2019 | Event News
29.04.2019 | Event News
17.04.2019 | Event News
15.07.2019 | Life Sciences
15.07.2019 | Power and Electrical Engineering
15.07.2019 | Life Sciences